- Home
- FEDU vs LPCN Comparison
FEDU vs LPCN Comparison
Compare FEDU & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEDU
- LPCN
- Stock Information
- Founded
- FEDU 2007
- LPCN 1997
- Country
- FEDU China
- LPCN United States
- Employees
- FEDU N/A
- LPCN N/A
- Industry
- FEDU
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- FEDU
- LPCN Health Care
- Exchange
- FEDU NYSE
- LPCN Nasdaq
- Market Cap
- FEDU 22.2M
- LPCN 19.4M
- IPO Year
- FEDU 2017
- LPCN N/A
- Fundamental
- Price
- FEDU $10.17
- LPCN $3.38
- Analyst Decision
- FEDU
- LPCN Strong Buy
- Analyst Count
- FEDU 0
- LPCN 1
- Target Price
- FEDU N/A
- LPCN $10.00
- AVG Volume (30 Days)
- FEDU 3.3K
- LPCN 33.0K
- Earning Date
- FEDU 12-20-2024
- LPCN 03-06-2025
- Dividend Yield
- FEDU 22.42%
- LPCN N/A
- EPS Growth
- FEDU N/A
- LPCN N/A
- EPS
- FEDU 0.12
- LPCN N/A
- Revenue
- FEDU $27,971,139.00
- LPCN $7,922,926.00
- Revenue This Year
- FEDU N/A
- LPCN N/A
- Revenue Next Year
- FEDU N/A
- LPCN N/A
- P/E Ratio
- FEDU $85.33
- LPCN N/A
- Revenue Growth
- FEDU 141.14
- LPCN N/A
- 52 Week Low
- FEDU $7.41
- LPCN $3.20
- 52 Week High
- FEDU $22.70
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- FEDU 48.25
- LPCN 30.99
- Support Level
- FEDU $9.78
- LPCN $3.42
- Resistance Level
- FEDU $10.77
- LPCN $3.62
- Average True Range (ATR)
- FEDU 0.53
- LPCN 0.26
- MACD
- FEDU 0.04
- LPCN -0.02
- Stochastic Oscillator
- FEDU 49.43
- LPCN 1.61
About FEDU FOUR SEASONS EDUCATION (CAYMAN) INC SPON ADS EACH REP 10 ORD SHS(R/S)
Four Seasons Education (Cayman) Inc is engaged in the provision of after-school education services for kindergarten, elementary and middle school students. The Company derives its revenue from learning services, tourism services, and learning technology and content solutions. The company is a comprehensive educational enterprise that provides research practice services, educational informatization equipment, high-quality educational resources, and teacher training, as well as a digital publishing business, and continues to expand in educational research and educational informatization.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.